Covid-19 New

More Info

Open access Aims and Scope Instructions Editorial Guidelines Licensing Copyright

Author's satisfaction with

  • Friendly and hassle-free publication process
  • Less production time of articles
  • Constructive peer-review
  • Enhancing journal reputation
  • Regular feedback system
  • Quick response to authors' queries

Read More

Recently Viewed

The Lived Experiences of Addiction Counselors and Applicatio Changes in Serum Markers of Atherogenesis and Hematological Generating eco-friendly electricity from rain water Percutaneous Closure of Post-myocardial Infarction Ventricul Value of Speckle Tracking Echocardiography in Prediction of

Read More

Most Viewed

Evaluation of Biostimulants Based on Recovered Protein Hydro Sinonasal Myxoma Extending into the Orbit in a 4-Year Old: A Feasibility study of magnetic sensing for detecting single-n Pediatric Dysgerminoma: Unveiling a Rare Ovarian Tumor Physical activity can change the physiological and psycholog

Read More

Open Journals

Clinical Images

For Authors Guide For Authors Benefits For Authors Article Processing Charge How To Write a Scientific Paper How To Write a Review Article Short Communication
For Reviewers Benefits For Reviewers How To Review Thanks To Reviewers
For Editors Benefits For Editors Thanks To Editors

Abstract

Research Article

Immunological background for treatments with biologicals in CRSwNP

L Klimek*, J Hagemann, I Casper, T Huppertz, A Bedbrook and J Bousquet

Published: 08 April, 2021 | Volume 5 - Issue 1 | Pages: 022-029

Background: Chronic rhinosinusitis (CRS) is a heterogeneous and multifactorial inflammatory disease of the nasal and paranasal mucosa. To date, no internationally standardized uniform classification has been developed for this disease.

Usually, a phenotype classification according to CRS with (CRSwNP) and without (CRSsNP) polyposis is performed. However, through a variety of studies, it has been shown that even within these phenotypes, different endotypes of CRS exist, each with a different underlying inflammatory pathophysiology. In this mini-review, we aim to outline the essential immunological processes in CRSwNP and to highlight the modern therapeutic options with biologics derived from this disease.

Methods: Current knowledge on the immunological and molecular processes of CRS, especially CRSwNP, was compiled by means of a structured literature review. Medline, PubMed, national/international trial and guideline registries as well as the Cochrane Library were all searched.

Results: Based on the current literature, the different immunological processes involved in CRS and nasal polyps were elaborated. Current studies on the therapy of eosinophilic diseases such as asthma and polyposis are presented and their results discussed.

Conclusion: Understanding the immunological basis of CRSwNP may help to develop new personalized therapeutic approaches using biologics. Currently, 2 biologics (dupilumab, omalizumab) have been approved for the therapy of CRSwNP (polyposis nasi) in Europe.

Read Full Article HTML DOI: 10.29328/journal.aaai.1001026 Cite this Article Read Full Article PDF

References

  1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology Supplement. Rhinology. 2012; 50: 1-12. PubMed: https://pubmed.ncbi.nlm.nih.gov/22469599/
  2. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, et al. Chronic rhinosinusitis in Europe--an underestimated disease. A GA(2)LEN study. Allergy. 2011; 66: 1216-1223. PubMed: https://pubmed.ncbi.nlm.nih.gov/21605125/
  3. Stuck BA, Beule A, Jobst D, Klimek L, Laudien M, et al. [Guideline for "rhinosinusitis"-long version : S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery]. HNO. 2018; 66: 38-74. PubMed: https://pubmed.ncbi.nlm.nih.gov/28861645/
  4. Rosenfeld RM, David A, Neil B, Dickson C, Steven E, et al. Clinical practice guideline on adult sinusitis. Otolaryngol Head Neck Surg. 2007; 137: 365-377. PubMed: https://pubmed.ncbi.nlm.nih.gov/17761281/
  5. Koennecke M, Klimek L, Mullol J, Gevaert P, Wollenberg B. Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo J Int. 2018; 27: 56-65. PubMed: https://pubmed.ncbi.nlm.nih.gov/29564208/
  6. Calus L, Van Zele T, Derycke L, Krysko O, Dutre T, et al. Local inflammation in chronic upper airway disease. Curr Pharm Des. 2012; 18: 2336-2346. PubMed: https://pubmed.ncbi.nlm.nih.gov/22390697/
  7. Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther. 2009; 11: 257. PubMed: https://pubmed.ncbi.nlm.nih.gov/20053303/
  8. Zygmunt B, Veldhoen M. T helper cell differentiation more than just cytokines. Adv Immunol. 2011; 109: 159-196. PubMed: https://pubmed.ncbi.nlm.nih.gov/21569915/
  9. Kaur D, Brightling C. OX40/OX40 ligand interactions in T-cell regulation and asthma. Chest. 2012; 141: 494-499. PubMed: https://pubmed.ncbi.nlm.nih.gov/22315115/
  10. Lane P. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J Exp Med. 2000; 191: 201-206. PubMed: https://pubmed.ncbi.nlm.nih.gov/10637265/
  11. Plager DA, Kahl JC, Asmann YW, Nilson AE, Pallanch JF, et al. Gene transcription changes in asthmatic chronic rhinosinusitis with nasal polyps and comparison to those in atopic dermatitis. PLoS One. 2010; 5: e11450. PubMed: https://pubmed.ncbi.nlm.nih.gov/20625511/
  12. Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006; 61: 1280-1289. PubMed: https://pubmed.ncbi.nlm.nih.gov/17002703/
  13. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 1993; 362: 245-248. PubMed: https://pubmed.ncbi.nlm.nih.gov/8384701/
  14. Ouyang W, Ranganath SH, Weindel K, Bhattacharya D, Murphy TL, et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity. 1998; 9: 745-755. PubMed: https://pubmed.ncbi.nlm.nih.gov/9846495/
  15. Derycke L, Eyerich S, Van Crombruggen K, Perez-Novo C, Holtappels G, et al. Mixed T helper cell signatures in chronic rhinosinusitis with and without polyps. PloS One. 2014; 9: e97581. PubMed: https://pubmed.ncbi.nlm.nih.gov/24911279/
  16. Danielsen A, Tynning T, Brokstad KA, Olofsson J, Davidsson A. Interleukin 5, IL6, IL12, IFN-gamma, RANTES and Fractalkine in human nasal polyps, turbinate mucosa and serum. Eur Arch Otorhinolaryngol. 2006; 263: 282-289. PubMed: https://pubmed.ncbi.nlm.nih.gov/16456693/
  17. Li Z, Zhang Y, Sun B. Current understanding of Th2 cell differentiation and function. Protein Cell. 2011; 2: 604-611. PubMed: https://pubmed.ncbi.nlm.nih.gov/21904976/
  18. Prussin C, Yin Y, Upadhyaya B. T(H)2 heterogeneity: Does function follow form? J Allergy Clin Immunol. 2010; 126: 1094-1098. PubMed: https://pubmed.ncbi.nlm.nih.gov/20951419/
  19. Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol. 1997; 99: 837-842. PubMed: https://pubmed.ncbi.nlm.nih.gov/9215253/
  20. Bachert C, Gevaert P, Holtappels G, Cuvelier C, van Cauwenberge P. Nasal polyposis: from cytokines to growth. Am J Rhinol. 2000; 14: 279-290. PubMed: https://pubmed.ncbi.nlm.nih.gov/11068652/
  21. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001; 14: 705-714. PubMed: https://pubmed.ncbi.nlm.nih.gov/11420041/
  22. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol. 2005; 175: 3463-3468. PubMed: https://pubmed.ncbi.nlm.nih.gov/16148087/
  23. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003; 24: 25-29. PubMed: https://pubmed.ncbi.nlm.nih.gov/12495721/
  24. Peters AT, Kato A, Zhang N, Conley DB, Suh L, et al. Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2010; 125: 397-403 e10. PubMed: https://pubmed.ncbi.nlm.nih.gov/20159251/
  25. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016; 137: 1449-1456 e4. PubMed: https://pubmed.ncbi.nlm.nih.gov/26949058/
  26. Keswani A, Chustz RT, Suh L, Carter R, Peters AT, et al. Differential expression of interleukin-32 in chronic rhinosinusitis with and without nasal polyps. Allergy. 2012; 67: 25-32. PubMed: https://pubmed.ncbi.nlm.nih.gov/21899560/
  27. Cho JS, Kim JA, Park JH, Park IH, Han IH, et al. Toll-like receptor 4-mediated expression of interleukin-32 via the c-Jun N-terminal kinase/protein kinase B/cyclic adenosine monophosphate response element binding protein pathway in chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2016; 6: 1020-1028. PubMed: https://pubmed.ncbi.nlm.nih.gov/27173130/
  28. Bai X, Kim SH, Azam T, McGibney MT, Huang H, et al. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol. 2010; 184: 3830-3840. PubMed: https://pubmed.ncbi.nlm.nih.gov/20190143/
  29. Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis. 2006; 65 Suppl 3: iii61-64. PubMed: https://pubmed.ncbi.nlm.nih.gov/17038476/
  30. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005; 22: 131-142. PubMed: https://pubmed.ncbi.nlm.nih.gov/15664165/
  31. Li W, Sun W, Liu L, Yang F, Li Y, et al. IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection. J Immunol. 2010; 185: 5056-5065. PubMed: https://pubmed.ncbi.nlm.nih.gov/20889550/
  32. Netea MG, Azam T, Lewis EC, Joosten LA, Wang M, et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanism. PLoS Med. 2006; 3: e277. PubMed: https://pubmed.ncbi.nlm.nih.gov/16903774/
  33. Nold MF, Nold-Petry CA, Pott GB, Zepp JA, Saavedra MT, et al. Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol. 2008; 181: 557-565. PubMed: https://pubmed.ncbi.nlm.nih.gov/18566422/
  34. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 178: 894-901. PubMed: https://pubmed.ncbi.nlm.nih.gov/18703789/
  35. Meyer N, Zimmermann M, Burgler S, Bassin C, Woehrl S, et al. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol. 2010; 125: 858-865. PubMed: https://pubmed.ncbi.nlm.nih.gov/20227751/
  36. Kang JW, Park YS, Lee DH, Kim MS, Bak Y, et al. Interaction network mapping among IL-32 isoforms. Biochimie. 2014; 101: 248-251. PubMed: https://pubmed.ncbi.nlm.nih.gov/24472437/
  37. Chin D, Harvey RJ. Nasal polyposis: an inflammatory condition requiring effective anti-inflammatory treatment. Curr Opin Otolaryngol Head Neck Surg. 2013; 21: 23-30. PubMed: https://pubmed.ncbi.nlm.nih.gov/23172039/
  38. Lam EP, Kariyawasam HH, Rana BM, Durham SR, McKenzie AN, et al. IL-25/IL-33-responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. J Allergy Clin Immunol. 2016; 137: 1514-1524. PubMed: https://pubmed.ncbi.nlm.nih.gov/26684290/
  39. Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015; 64: 121-130. PubMed: https://pubmed.ncbi.nlm.nih.gov/25838086/
  40. Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med. 2007; 204: 1837-1847. PubMed: https://pubmed.ncbi.nlm.nih.gov/17635955/
  41. Shin HW, Kim DK, Park MH, Eun KM, Lee M, et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2015; 135: 1476-1485. PubMed: https://pubmed.ncbi.nlm.nih.gov/25725991/
  42. Kimura S, Pawankar R, Mori S, Nonaka M, Masuno S, et al. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy Asthma Immunol Res. 2011; 3: 186-193. PubMed: https://pubmed.ncbi.nlm.nih.gov/21738884/
  43. Liu T, Li TL, Zhao F, Xie C, Liu AM, et al. Role of thymic stromal lymphopoietin in the pathogenesis of nasal polyposis. Am J Med Sci. 2011; 341: 40-47. PubMed: https://pubmed.ncbi.nlm.nih.gov/20924287/
  44. Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013; 132: 593-600. PubMed: https://pubmed.ncbi.nlm.nih.gov/23688414/
  45. Nagarkar DR, Poposki JA, Comeau MR, Biyasheva A, Avila PC, et al. Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin. J Allergy Clin Immunol. 2012; 130: 225-232. PubMed: https://pubmed.ncbi.nlm.nih.gov/22633328/
  46. Reh DD, Wang Y, Ramanathan M, Lane AP. Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy. 2010; 24: 105-109. PubMed: https://pubmed.ncbi.nlm.nih.gov/20338108/
  47. Kim DK, Jin HR, Eun KM, Mo JH, Cho SH, et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax. 2017; 72: 591-593. PubMed: https://pubmed.ncbi.nlm.nih.gov/28242750/
  48. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008; 223: 20-38. PubMed: https://pubmed.ncbi.nlm.nih.gov/18613828/
  49. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008; 121: 1484-1490. PubMed: https://pubmed.ncbi.nlm.nih.gov/18539196/
  50. Castano R, Bosse Y, Endam LM, Desrosiers M. Evidence of association of interleukin-1 receptor-like 1 gene polymorphisms with chronic rhinosinusitis. Am J Rhinol Allergy. 2009; 23: 377-384. PubMed: https://pubmed.ncbi.nlm.nih.gov/19671251/
  51. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 2011; 12: 1055-1062. PubMed: https://pubmed.ncbi.nlm.nih.gov/21909091/
  52. Robinette ML, Colonna M. Immune modules shared by innate lymphoid cells and T cells. J Allergy Clin Immunol. 2016; 138: 1243-1251. PubMed: https://pubmed.ncbi.nlm.nih.gov/27817796/
  53. Kim HY, Chang YJ, Subramanian S, Lee HH, Albacker LA, et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol. 2012; 129: 216-227. PubMed: https://pubmed.ncbi.nlm.nih.gov/22119406/
  54. Morita H, Moro K, Koyasu S. Innate lymphoid cells in allergic and nonallergic inflammation. J Allergy Clin Immunol. 2016; 138: 1253-1264. PubMed: https://pubmed.ncbi.nlm.nih.gov/27817797/
  55. Ho J, Bailey M, Zaunders J, Mrad N, Sacks R, et al. Cellular comparison of sinus mucosa vs polyp tissue from a single sinus cavity in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2015; 5: 14-27. PubMed: https://pubmed.ncbi.nlm.nih.gov/25332132/
  56. Ho J, Bailey M, Zaunders J, Mrad N, Sacks R, et al. Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia. Clin Exp Allergy. 2015; 45: 394-403. PubMed: https://pubmed.ncbi.nlm.nih.gov/25429730/
  57. Beck LA, Stellato C, Beall LD, Schall TJ, Leopold D, et al. Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. J Allergy Clin Immunol. 1996; 98: 766-780. PubMed: https://pubmed.ncbi.nlm.nih.gov/8876553/
  58. Davidsson A, Danielsen A, Viale G, Olofsson J, Dell'Orto P, et al. Positive identification in situ of mRNA expression of IL-6, and IL-12, and the chemotactic cytokine RANTES in patients with chronic sinusitis and polypoid disease. Clinical relevance and relation to allergy. Acta Otolaryngol. 1996; 116: 604-610. PubMed: https://pubmed.ncbi.nlm.nih.gov/8831850/
  59. Allen JS, Eisma R, LaFreniere D, Leonard G, Kreutzer D. Characterization of the eosinophil chemokine RANTES in nasal polyps. The Annals of otology, rhinology, and laryngology. 1998; 107: 416-420. PubMed: https://pubmed.ncbi.nlm.nih.gov/9596221/
  60. Meyer JE, Bartels J, Gorogh T, Sticherling M, Rudack C, et al. The role of RANTES in nasal polyposis. Am J Rhinol. 2005; 19: 15-20. PubMed: https://pubmed.ncbi.nlm.nih.gov/15794069/
  61. Chen YS, Arab SF, Westhofen M, Lorenzen J. Expression of interleukin-5, interleukin-8, and interleukin-10 mRNA in the osteomeatal complex in nasal polyposis. Am J Rhinol. 2005; 19: 117-123. PubMed: https://pubmed.ncbi.nlm.nih.gov/15921209/
  62. Kostamo K, Sorsa T, Leino M, Tervahartiala T, Alenius H, et al. In vivo relationship between collagenase-2 and interleukin-8 but not tumour necrosis factor-alpha in chronic rhinosinusitis with nasal polyposis. Allergy. 2005; 60: 1275-1279. PubMed: https://pubmed.ncbi.nlm.nih.gov/16134994/
  63. Scavuzzo MC, Fattori B, Ruffoli R, Rocchi V, Carpi A, et al. Inflammatory mediators and eosinophilia in atopic and non-atopic patients with nasal polyposis. Biomed Pharmacother. 2005; 59: 323-329. PubMed: https://pubmed.ncbi.nlm.nih.gov/15935609/
  64. Wang X, Zhang N, Bo M, Holtappels G, Zheng M, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016; 138: 1344-1353. PubMed: https://pubmed.ncbi.nlm.nih.gov/27544740/
  65. Poposki JA, Uzzaman A, Nagarkar DR, Chustz RT, Peters AT, et al. Increased expression of the chemokine CCL23 in eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2011; 128: 73-81. PubMed: https://pubmed.ncbi.nlm.nih.gov/21497884/
  66. Bachert C, Van Cauwenberge PB. Inflammatory mechanisms in chronic sinusitis. Acta Otorhinolaryngol Belg. 1997; 51: 209-217. PubMed: https://pubmed.ncbi.nlm.nih.gov/9444369/
  67. Fundova P, Funda DP, Kovar D, Holy R, Navara M, Tlaskalova-Hogenova H. Increased expression of chemokine receptors CCR1 and CCR3 in nasal polyps: molecular basis for recruitment of the granulocyte infiltrate. Folia Microbiol (Praha). 2013; 58: 219-224. PubMed : https://pubmed.ncbi.nlm.nih.gov/23054685/
  68. Patel VP, Kreider BL, Li Y, Li H, Leung K, et al. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med. 1997; 185: 1163-1172. PubMed: https://pubmed.ncbi.nlm.nih.gov/9104803/
  69. Novak H, Muller A, Harrer N, Gunther C, Carballido JM, et al. CCL23 expression is induced by IL-4 in a STAT6-dependent fashion. J Immunol. 2007; 178: 4335-4341. PubMed: https://pubmed.ncbi.nlm.nih.gov/17371990/
  70. Peterson S, Poposki JA, Nagarkar DR, Chustz RT, Peters AT, et al. Increased expression of CC chemokine ligand 18 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2012; 129: 119-127. PubMed: https://pubmed.ncbi.nlm.nih.gov/21943944/
  71. Islam SA, Ling MF, Leung J, Shreffler WG, Luster AD. Identification of human CCR8 as a CCL18 receptor. J Exp Med. 2013; 210: 1889-1898. PubMed: https://pubmed.ncbi.nlm.nih.gov/23999500/
  72. Kato A, Peters A, Suh L, Carter R, Harris KE, et al. Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2008; 121: 1385-1392. PubMed: https://pubmed.ncbi.nlm.nih.gov/18410958/
  73. Polzehl D, Moeller P, Riechelmann H, Perner S. Distinct features of chronic rhinosinusitis with and without nasal polyps. Allergy. 2006; 61: 1275-1279. PubMed : https://pubmed.ncbi.nlm.nih.gov/17002702/
  74. Patadia M, Dixon J, Conley D, Chandra R, Peters A, et al. Evaluation of the presence of B-cell attractant chemokines in chronic rhinosinusitis. Am J Rhinol Allergy. 2010; 24: 11-16. PubMed: https://pubmed.ncbi.nlm.nih.gov/20109310/
  75. Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014; 370: 2102-2110. PubMed: https://pubmed.ncbi.nlm.nih.gov/24846652/
  76. Bel EH, Ortega HG, Pavord ID. Glucocorticoids and mepolizumab in eosinophilic asthma. N Engl J Med. 2014; 371: 2434-2444. PubMed: https://pubmed.ncbi.nlm.nih.gov/25517713/
  77. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013; 368: 2455-2466. PubMed: https://pubmed.ncbi.nlm.nih.gov/23688323/
  78. Pauwels B, Jonstam K, Bachert C. Emerging biologics for the treatment of chronic rhinosinusitis. Expert Rev Clin Immunol. 2015; 11: 349-361. PubMed: https://pubmed.ncbi.nlm.nih.gov/25651905/
  79. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108: 184-190. PubMed: https://pubmed.ncbi.nlm.nih.gov/11496232/
  80. Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. J Allergy Clin Immunol. 2015; 136: 1431-1440. PubMed: https://pubmed.ncbi.nlm.nih.gov/26654192/
  81. Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010; 126: 962-968. PubMed: https://pubmed.ncbi.nlm.nih.gov/20810157/
  82. Lehrer E, Mullol J, Agredo F, Alobid I. Management of chronic rhinosinusitis in asthma patients: is there still a debate? Curr Allergy Asthma Rep. 2014; 14: 440. PubMed: https://pubmed.ncbi.nlm.nih.gov/24682772/
  83. Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014; 28: 192-198. PubMed: https://pubmed.ncbi.nlm.nih.gov/24980230/
  84. Grundmann SA, Hemfort PB, Luger TA, Brehler R. Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol. 2008; 121: 257-258. PubMed: https://pubmed.ncbi.nlm.nih.gov/18206513/
  85. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clinical and experimental allergy: J British Soc Allergy Clin Immunol. 2005; 35: 408-416. PubMed: https://pubmed.ncbi.nlm.nih.gov/15836747/
  86. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010; 48: 318-324. PubMed: https://pubmed.ncbi.nlm.nih.gov/21038023/
  87. Vennera MDC, Sabadell C, Picado C, Spanish Omalizumab R. Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma. Thorax. 2018. 73: 782-784. PubMed: https://pubmed.ncbi.nlm.nih.gov/29079610/
  88. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013; 131: 110-116. PubMed: https://pubmed.ncbi.nlm.nih.gov/23021878/
  89. Felix-Redondo FJ, Fernandez-Berges D, Calderon A, Consuegra-Sanchez L, Lozano L, et al. Prevalence of left-ventricular hypertrophy by multiple electrocardiographic criteria in general population: Hermex study. J Hypertens. 2012; 30: 1460-1467. PubMed: https://pubmed.ncbi.nlm.nih.gov/22573128/
  90. Calderon MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol. 2012; 129: 929-934. PubMed: https://pubmed.ncbi.nlm.nih.gov/22244595/
  91. Valenta R, Laffer S, Vrtala S, Gronlund H, Elfman L, et al. Recombinant allergens. Steps on the way to diagnosis and therapy of type I allergy. Adv Exp Med Biol. 1996; 409: 185-196. PubMed: https://pubmed.ncbi.nlm.nih.gov/9095240/
  92. Gauvreau GM, Arm JP, Boulet LP, Leigh R, Cockcroft DW, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol. 2016; 138: 1051-1059. PubMed: https://pubmed.ncbi.nlm.nih.gov/27185571/
  93. Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clinical and experimental allergy. J British Soc Allergy Clin Immunol. 2014; 44: 1371-1385. PubMed: https://pubmed.ncbi.nlm.nih.gov/25200415/
  94. Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Translational Med. 2014; 6: 243ra85. PubMed: https://pubmed.ncbi.nlm.nih.gov/24990880/
  95. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005; 60: 801-807. PubMed: https://pubmed.ncbi.nlm.nih.gov/15876311/
  96. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respira Crit Care Med. 2007; 176: 1062-1071. PubMed: https://pubmed.ncbi.nlm.nih.gov/17872493/
  97. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respira Crit Care Med. 2003; 167: 199-204. PubMed: https://pubmed.ncbi.nlm.nih.gov/12406833/
  98. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New Engl J Med. 2014; 371: 1189-1197. PubMed: https://pubmed.ncbi.nlm.nih.gov/25199060/
  99. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006; 118: 1133-1141. PubMed: https://pubmed.ncbi.nlm.nih.gov/17088140/
  100. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011; 128: 989-995. PubMed: https://pubmed.ncbi.nlm.nih.gov/21958585/
  101. Mepolizumab in Nasal Polyposis. https://clinicaltrials.gov/ct2/show/NCT01362244
  102. Effect of Mepolizumab in Severe Bilateral Nasal Polyps. https://clinicaltrials.gov/ct2/show/NCT03085797
  103. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015; 3: 355-366. PubMed: https://pubmed.ncbi.nlm.nih.gov/25736990/
  104. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184: 1125-1132. PubMed: https://pubmed.ncbi.nlm.nih.gov/21852542/
  105. Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab. https://clinicaltrials.gov/ct2/show/NCT03369574
  106. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010; 125: 1344-1345. PubMed: https://pubmed.ncbi.nlm.nih.gov/20513525/
  107. Berair R, Pavord ID. Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma. Curr Allergy Asthma Rep. 2013; 13: 469-476. PubMed: https://pubmed.ncbi.nlm.nih.gov/23904099/
  108. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013; 132: 1086-1096. PubMed: https://pubmed.ncbi.nlm.nih.gov/23866823/
  109. Mahdavinia M, Carter RG, Ocampo CJ, Stevens W, Kato A, et al. Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity. J Allergy Clin Immunol. 2014; 133: 1759-1763. PubMed: https://pubmed.ncbi.nlm.nih.gov/24636088/
  110. Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis (OSTRO). https://clinicaltrials.gov/ct2/show/NCT03401229
  111. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, et al. Lebrikizumab treatment in adults with asthma. New Engl J Med. 2011; 365: 1088-1098.
  112. De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014; 133: 989-996. PubMed: https://pubmed.ncbi.nlm.nih.gov/24582316/
  113. Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol. 2013; 132: 567-574. PubMed: https://pubmed.ncbi.nlm.nih.gov/23726041/
  114. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. European respiratory review. J Eur Respir Soc. 2010; 19: 46-54. PubMed: https://pubmed.ncbi.nlm.nih.gov/20956165/
  115. Scheerens H, Arron JR, Zheng Y, Putnam WS, Erickson RW, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clinical and experimental allergy. J British Soc Allergy Clin Immunol. 2014; 44: 38-46. PubMed: https://pubmed.ncbi.nlm.nih.gov/24131304/
  116. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004; 114: 851-857. PubMed: https://pubmed.ncbi.nlm.nih.gov/15480326/
  117. Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Translational Med. 2015; 7: 301ra129. PubMed: https://pubmed.ncbi.nlm.nih.gov/26290411/
  118. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respirat Criti Care Med. 2010; 181: 788-796. PubMed: https://pubmed.ncbi.nlm.nih.gov/20056900/
  119. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007; 370: 1422-1431. PubMed: https://pubmed.ncbi.nlm.nih.gov/17950857/
  120. Wenzel S, Castro M, Corren J, Maspero J, Wang L, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016; 388: 31-44. PubMed: https://pubmed.ncbi.nlm.nih.gov/27130691/
  121. Wenzel SE, Wang L, Pirozzi G. Dupilumab in persistent asthma. New Engl J Med. 2013; 369: 1276. PubMed: https://pubmed.ncbi.nlm.nih.gov/24066755/
  122. Wechsler ME. Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma. New Engl J Med. 2013; 368: 2511-2513. PubMed: https://pubmed.ncbi.nlm.nih.gov/23688322/
  123. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016; 315: 469-479. PubMed: https://pubmed.ncbi.nlm.nih.gov/26836729/
  124. Barajas-Espinosa A, Ochoa-Cortes F, Moos MP, Ramirez FD, Vanner SJ, et al. Characterization of the cysteinyl leukotriene 2 receptor in novel expression sites of the gastrointestinal tract. Am J Pathol. 2011; 178: 2682-2689. PubMed: https://pubmed.ncbi.nlm.nih.gov/21641390/
  125. Stock C, Moosbauer D, Zugmann S, Simbeck T, Amereller M, et al. A novel method for in situ measurement of solubility via impedance scanning quartz crystal microbalance studies. Chem Commun (Camb). 2011; 47: 6984-6986. PubMed: https://pubmed.ncbi.nlm.nih.gov/21594264/
  126. Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Mayers I, et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clinical and experimental allergy. J British Soc Allergy Clin Immunol. 2014; 44: 29-37. PubMed: https://pubmed.ncbi.nlm.nih.gov/24224471/
  127. Pfaar O, Mosges R, Hormann K, Klimek L. [Cluster immunotherapy of persistent allergic rhinoconjunctivitis. Safety aspects of induction therapy with mite depot allergen preparations]. Hno. 2009; 57: 1099-1105. PubMed: https://pubmed.ncbi.nlm.nih.gov/19585090/
  128. Klimek L, Pfaar O, Grevers G. Therapeutical options in allergic rhinitis. MMW Fortschr Med. 2009; 151: 31-34.
  129. Pfaar O, Anders C, Klimek L. Clinical outcome measures of specific immunotherapy. Curr Opin Allergy Clin Immunol. 2009; 9: 208-213. PubMed: https://pubmed.ncbi.nlm.nih.gov/19365259/
  130. Pfaar O, Klimek L, Fischer I, Sieber J, Amoroso S, et al. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Int Arch Allergy Immunol. 2009; 150: 102-108. PubMed: https://pubmed.ncbi.nlm.nih.gov/19339808/
  131. Pfaar O, Raap U, Holz M, Hormann K, Klimek L. Pathophysiology of itching and sneezing in allergic rhinitis. Swiss Med Wkly. 2009; 139: 35-40. PubMed: https://pubmed.ncbi.nlm.nih.gov/19169901/
  132. Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Therapeut. 2012; 135: 327-336. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587973/
  133. Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood. 2003; 101: 5014-5020. PubMed: https://pubmed.ncbi.nlm.nih.gov/12609831/
  134. Na HJ, Hudson SA, Bochner BS. IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils. Cytokine. 2012; 57: 169-174. PubMed: https://pubmed.ncbi.nlm.nih.gov/22079334/
  135. Nutku E, Hudson SA, Bochner BS. Mechanism of Siglec-8-induced human eosinophil apoptosis: role of caspases and mitochondrial injury. Biochem Biophysi Res Commun. 2005; 336: 918-924. PubMed: https://pubmed.ncbi.nlm.nih.gov/16157303/
  136. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Criti Care Med. 2009; 179: 549-558. PubMed: https://pubmed.ncbi.nlm.nih.gov/19136369/
  137. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol. 2008; 121: 5-10. PubMed: https://pubmed.ncbi.nlm.nih.gov/18036647/
  138. Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008; 178: 1002-1008. PubMed: https://pubmed.ncbi.nlm.nih.gov/18787222/
  139. De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, et al. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017; 7: 22. PubMed: https://pubmed.ncbi.nlm.nih.gov/28706720/
  140. Bachert C, Gevaert P, Hellings P. Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps. J Allergy Clin Immunol Pract. 2017; 5: 1512-1516. PubMed: https://pubmed.ncbi.nlm.nih.gov/28526278/
  141. Kim DW, Cho SH. Emerging Endotypes of Chronic Rhinosinusitis and Its Application to Precision Medicine. Allergy Asthma Immunol Res. 2017; 9: 299-306. PubMed: https://pubmed.ncbi.nlm.nih.gov/28497916/
  142. Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, et al. Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: Position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int. 2017; 26: 16-24. PubMed: https://pubmed.ncbi.nlm.nih.gov/28217433/

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Contact

Editorial Office Emails:

info@hspioa.org

amelia.sandra@hspioa.us

elena.maya@hspioa.us

Select by Volume & Issue

Submit Manuscript Information for Authors Advisory Board Rss Feed Articles Rss Feed

Most Viewed Keywords

University/Institution

Select and search by University/Institution.

Articles by Country

Select and search by country to get related articles.

Testmonials

I would like to thank JPRA for taking this decision. I understand the effort it represents for you. I'm truly happy to have the paper published in JPRA. And I'll certainly consider JPRA for my next publications as I was satisfied of the service provided, the efficiency and promptness of the interactions we had.

Emmanuel BUSATO

Publishing with the International Journal of Clinical and Experimental Ophthalmology was a rewarding experience as review process was thorough and brisk. Their visibility online is second to none as their published articles appear in all search engines. I will encourage researchers to publish with them.

Elizabeth Awoyesuku

“The choice to submit the forensic case study to the Journal of Addiction Therapy and Research was dictated by the match between the content and the potential readership. The publication process proved to be expedient and we were provided with constructive feedback from reviewers. The final article layout is attractive and conforms to standards. All-in-all, it has been a rewarding process.”

Elisabeth H Wiig

Archives of Vascular Medicine is one of the top class journal for vascular medicine with highly interesting topics. You did a professional and great Job!

Elias Noory

Thank you very much. I think the review process and all of what concerns the administration of the publication concerning our paper has been excellent. The nice and quick answers have been very good I think.

Doris Nilsson

Journal of Pulmonary and Respiratory Research is good journal for respiratory research purposes. It takes 2-3 weeks maximum for review of the manuscript to get published and any corrections to be made in the manuscript. It needs good articles and studies to get publish in the respiratory medicine. I am really glad that this journal editors helped me to get my case report published.

Divya Khanduja

Thanks you and your colleague for the great help for our publication. You always provide prompt responses and high quality of service. I am so happy to have you working with me. Thanks again!

Diana (Ding) Dai

Service and process were excellent as was the “look” of the article when published.

Deane Waldman

Great, thank you! It was very efficient working w/ your group. Very thorough reviews (i.e., plagiarism, peer, etc.). Would certainly recommend that future authors consider working w/ your group.

David W Brett

Your services are very good

Chukwuka Ireju Onyinye

I very much appreciate the humanitarian services provided in my stead by this journal/publisher. It exhibits total absence of editorial impertinence. As an Author, I have been guided to have a fruitful experience. The editorial care is highly commendable.

Chrysanthus Chukwuma

"An amazing experience with the Journal of Advanced Pediatrics and Child Health. Very fast blind review with pertinent corrections and suggestions. I highly recommand both the journal and the editor."

Chaimae Khairoun

The submission is very easy and the time from submission to response from the reviewers is short. Correspondence with the journal is nice and rapid.

Catrin Henriksson

The Clinical Journal of Obstetrics and Gynecology is an open access journal focused on scientific knowledge publication with emphasis laid on the fields of Gynecology and Obstetrics. Their services toward us have been encouraging through their kindness and respect. Great consideration has been given to us as young budding researchers and we are very grateful for this.

Carole Assontsa

During the process your positive communication, prompt feedback and professional approach is very highly appreciated. We would like to thank you very much for your support.

Can Vuran

I do appreciate for your service including submission, analysis, review, editorial and publishing process. I believe these esteemed journal enlighten the science with its high-quality personel.

Bora Uysal

I am very much pleased with the fast track publication by your reputed journal's editorial team. It is really helpful for researchers like me from developing nations. I strongly recommend your journal for publication.

Badri Kumar Gupta

It has been a fabulous journey writing articles for your journal because of the encouragement you people provide for writers from developing nations like India. Kindly continue the same. Looking forward for a long term association.

Badareesh Lakshminarayana

Many thanks for publishing my article in your great journal and the friendly and hassle-free publication process, the constructive peer-review, the regular feedback system, and the Quick response to any queries.

Azab Elsayed Azab

I would like to thank this journal for publishing my Research Article. Something I really appreciate about this journal is, they did not take much time from the day of Submission to the publishing date. Looking forward to have more publications in future.

Ayush Chandra

Submission of paper was smooth, the review process was fast. I had excellent communication and on time response from the editor.

Ayokunle Dada

Your service is very good and fast reply, also your service understand our situation and support us to publication our articles.

Ayman M Abu Mustafa

Really good service with prompt response. Looking forward to having long lasting relationship with your journal

Avishek Bagchi

Your service is excellent. Processing and editing were very fast. I hope to publish more of my works in your journal.

Ausraful Islam

I wanna to thank Clinical Journal of Nursing Care and Practice for its effort to review and publish my manuscript. This is reputable journal. Thank you!

Atsedemariam Andualem

“It was a delightful experience publishing my manuscript with the Clinical Journal of Obstetrics and Gynecology. They offered me lots of opportunities I never had from most publishing houses and their prompt services are greatly appreciated.”

Asafo Jones

I hope to ability to make some new investigation and publish in Your Company in future.

Artur Stopyra

I like the quality of the print & overall service. The paper looks quite impressive. Hope this will attract interested readers. All of you have our best wishes for continued success.

Arshad Khan

Your big support from researchers around the world is the best appreciation from your scientific teams. We believe that there should be no barrier in science and you make it real and this motto come true.

Arefhosseinir Rafi

Your journal co-operation is very appreciable and motivational. I am really thankful to your journal and team members for the motivation and collaboration to publish my work.

Assistant Professor, UCLAS Uttaranchal University, Dehradun, India

Archna Dhasmana

I am glad to submit the article to Heighten Science Publications as it has a very smooth and fast peer-review process, which enables the researchers to communicate their work on time.

Anupam M

This is to specify that I have had an extensive and detailed interaction with the Editorial team of Annals of Clinical Gastroenterology and Hepatology, USA, lasting over a significant period of time. My interaction has been extremely pleasant, especially with Ms Allie Smith, as I find the communication quite inspiring and crystal clear. The attitude of aforesaid individuals is quite helpful and guiding in pertinent instances. It has been a commemorative journey so far working with the Journal and I hope that the symbiosis will continue, evolve and flourish in the forthcoming years. I wish the journal, related personnel and aforementioned individuals a fruitful, successful run.

New Delhi, India

Anubha Bajaj

We appreciate the fact that you decided to give us full waiver for the applicable charges and approve the final version. You did an excellent job preparing the PDF version. Of course we will consider your magazine for our future submissions and we will pay the applicable fees then.

Anna Dionysopoulou

''Co-operation of Archives of Surgery and Clinical Research journal is appreciable. I'm impressed at the promptness of the publishing staff and the professionalism displayed. Thank you very much for your support, help and encouragement.''

Anıl Gokce

Congratulations for the excellence of your journal and high quality of its publications.

Angel MARTIN CASTELLANOS

The service from the journal staff has been excellent.

Andy Smith

I was very pleased with the quick editorial process. We are sure that our paper will have great visibility, among other things due to its open access. We believe in science accessible to all.

Anderson Fernando de Souza

It was a great experience publishing through JCICM. The article has reached out to several institutions. Appreciate your professional work. Hope to work with you again

Anas Wardeh

Publishing an article is a long process, but working with your publication department made things go smoothly, even though the process took exactly 5 months from the time of submitting the article till the time I have favourable response, the missing part is the peer review details, which is essential in self auditing and future improvement, overall experience was excellent giving your understanding of the situation of lack of financial institution support.

Anas Diab

I think that Heighpubs very good. You are very helpful. Thank you for everything.

Ana Ribeiro

Regarding to be services, we note that are work with high standards of professionalism translated into quick response, efficiency which makes communication accessible. Furthermore, I believe to be much inviting for the submission of future works for publication purposes.

Amélia João Alice Nkutxi

I would like to mention that I had a wonderful experience working with HSPI. The whole process right from manuscript submission to peer review till the publication of the article was very prompt & efficient. I wish you good luck for the future.

Amarjeet Gambhir

Once I submitted the manuscript, the response time of the reviewers was very fast. The fine-tuning of the galley proof was likewise prompt. I believe the journal provide a valuable outlet to disseminate physical rehabilitation scientific knowledge to the clinical community. Respectfully. Dr. Alon

Alon

We really appreciate and thanks the full waiver you provide for our article. We happy to publish our paper in your journal. Thank you very much for your good support and services.

Ali Abusafia

It was a real pleasure working with your team. The review was done fast, and it was very clear, the editing was flawless, the article was published quickly compared to other journals, and everyone was understanding and helpful. I will gladly recommend this journal to my acquaintances in academia.

Alexandra Cozma

To the editorial team at HSPI and the Journal of Clinical Nephrology: Thank you so much for your hard work and collaboration in bringing our article to life. Your staff was responsive, flexible, and communicative and made the process smooth and easy. Thank you!

Alejandro Munoz

Dear colleagues! I am satisfied with our cooperation with you. Your service is at a high level. I hope for a future relationship. Let me know if I can get a paper version of the magazine with my articles from you. I see them on the Internet.

Aksenov V.V

"This is my first time publishing with the journal/publisher. I am impressed at the promptness of the publishing staff and the professionalism displayed. Thank you for encouraging young researchers like me!"

Ajite Kayode

I want to thank you for our collaboration. You were fast and effective with a positive spirit of teamwork. I am truly excited from our collaboration. You were like always fast, efficient and accurate. I hope that in the near future we will collaborate again.

Aikaterini Solomou

In my opinion, you provide a very fast and practical service.

Ahmet Eroglu

Great, We are too comfortable with the process including the peer review process and quality. But, the journal should be indexed in different databases such scopus.

Afework Edmealem

We really appreciate your efforts towards our article, the professional way you handle our request for exemption from charges. It was a great honor for us to publish in your magazine.

Achraf elbakkaly

I really liked the ease of submitting my manuscript in the HSPI journal. Further, the peer review was timely completed and I was communicated the final decision on my manuscript within 10 days of submission which is really appreciable. I strongly recommend all the scientists and researchers to submit their work in this journal”

Abu Bashar

My candid opinion is that the service you render is second to none. My favourite part is the prompt response to issue, really i value that.

Abiodun Akanbi Adeogun

Thank you very much for accepting our manuscript in your journal “International Journal of Clinical Virology”. We are very thankful to the esteemed team for timely response and quick review process. The editorial team of International Journal of Clinical Virology is too cooperative and well-mannered during the publication process. We are hopeful to publish many quality papers in your journal and I suggest the International Journal of Clinical Virology to all of my colleagues, researchers and friends to publish their research here.

Abdul Baset

I, Muhammad Sarwar Khan, am serving as Editor on Archives of Biotechnology and Biomedicine (ABB). I submitted an editorial titled, 'Edible vaccines to combat Infectious Bursal Disease of poultry' for publication in ABB. After submitting the manuscript; the services rendered by the management and technical personnel to handle and process the manuscript were marvelous. Plagiarism report was shared with me with complements before reviewers' comments, All steps including article processing and service charges were well taken care of keeping in view the author's interest/preference. All together, it was an encouraging and wonderful experience working with ABB personnel.

University of Agriculture, Pakistan

Muhammad Sarwar Khan

Your journal has accomplished its intended mission of providing very effective and efficient goals in dealing with submissions, conducting the reviewing process and in publishing accepted manuscripts in a timely manner. Keep up the great work and services that you provide.

University of Jacqmar, Inc., USA

John St. Cyr

I am to express my view that Heighten Science Publications are reliable quick even after peer review process. I hope and wish the publications will go a long way in disseminating science to many interested in scientific research.

College of Fisheries, CAU(I), Tripura, India

Ajit Kumar Roy

The Journal Clinical Nephrology provides a good opportunity for readers to stay updated in the field of clinical nephrology. Additionally - it provides a good opportunity for authors to publish their work. 1. Publication of the accepted manuscripts is sufficiently rapid. 2. The trust factor between the journal and me, as an author, is very important and well preserved. 3. Peer review process very rapid and effective.

Assaf Harofeh Medical Center, Israel

Leonid Feldman

In 2017, I submitted a manuscript to the journal Archives of Biotechnology and Biomedicine belonging to Heighten Science Publications Corporation. Within one week I already received the response from the editor. All processing steps were really fast so in terms of a speedy publication I can particularly recommend the journal Archives of Biotechnology and Biomedicine. The responsible contact person of the journal was always available, which gives a trustworthy impression to the author. Also the peer review process was clear and constructive. So from my experience with Heighten Science Publications Corporation I can recommend publishing there.

University of Tubingen, Germany

Yvonne Mast

We thank to the heighten science family, who speed up the publication of our article and provide every support.

Mehmet Besir

The services of the journal were excellent. The most important thing for an author is the speed of the peer review which was really fast here. They returned in a few days and immediately replied all of my questions. I want to refer this platform to all scholars. Many thanks.

Eastern Mediterranean University, Cyprus

Zehra Guchan TOPCU

Thank you for your attitude and support. I am sincerely grateful to you and the entire staff of the magazine for the high professionalism and fast quality work. Thank you very much!

USA

Igor Klepikov

Thank you and your company for effective support of authors which are very much dependable on the funds gambling for science in the different countries of our huge and unpredictable world. We are doing our work and should rely on a teams like Galley Proof-HSPC. Great success to all of you for the 2019th! Be well all the year long.

Russia

Victor V Apollonov

The editorial process was quickly done. The galley proof was sent within a week after being accepted for publication. The editorial team was very helpful and responded promptly.

India

Rohit Kulshrestha

Publishing with the International Journal of Clinical and Experimental Ophthalmology was a rewarding experience as review process was thorough and brisk. Their visibility online is second to none as their published articles appear in all search engines. I will encourage researchers to publish with them.

University of Port Harcourt Teaching Hospital, Nigeria

Dr. Elizabeth A Awoyesuku

"It was a pleasure to work with the editorial team of the journal on the submission of the manuscript. The team was professional, fast, and to the point".

NC A&T State University, USA

Moran Sciamama-Saghiv

Submission of paper was smooth, the review process was fast. I had excellent communication and on time response from the editor.

Ekiti State University Teaching Hospital, Nigeria

Ayokunle Dada

I am delighted and satisfied with. Heighten Science Publications as my manuscript was thoroughly assessed and published on time without delay. Keep up the good work.

Ido-Ekiti/Afe Babalola University, Nigeria

Dr. Shuaib Kayode Aremu

"This is my first time publishing with the journal/publisher. I am impressed at the promptness of the publishing staff and the professionalism displayed. Thank you for encouraging young researchers like me!"

Ekiti State University, Nigeria

Adebukola Ajite

I wanna to thank clinical journal of nursing care and practice for its effort to review and publish my manuscript. This is reputable journal. Thank you!

Wollo University, Ethiopia

Atsedemariam Andualem

We appreciate your approach to scholars and will encourage you to collaborate with your organization, which includes interesting and different medical journals. With the best wishes of success, creativity and joy in life, prosperity in the medical field.

Ivano- Frankivsk National Medical University, Ukraine

Nataliya Kitsera

Thank you very much for your support and encouragement. I am truly impressed by your tolerance and support. Thank you very much

Diaverum: PADC, Jeddah, Saudi Arabia

Nasrulla Abutaleb

You are such a nice person. Your journal co-operation is very appreciable and motivational.

Department of Biotechnology, Uttaranchal college of Applied and Life Sciences, Uttaranchal University, Dehradun, Uttarakhand, India

Archna Dhasmana

“Mobile apps and wearable technology are becoming ubiquitous in our environment. Their integration with healthcare delivery is just beginning to take shape. The early results are promising and the possibilities great."

BS, PharmD., MBA, CPHIMS, FHIMSS, Adjunct Professor, Global Healthcare Management, MCPHS University, Chief Strategy Offi cer, MedicaSoft, Senior Advisor, National Health IT (NHIT) Collaborative for Underserved, New York HIMSS, National Liaison, Health 2.0 Boston, Past Chair, Chair Innovation, USA

Helen Figge

“The choice to submit the forensic case study to the Journal of Addiction Therapy and Research was dictated by the match between the content and the potential readership. The publication process proved to be expedient and we were provided with constructive feedback from reviewers. The final article layout is attractive and conforms to standards. All-in-all, it has been a rewarding process.”

Ph.D, Boston University Department of Communication Sciences and Disorders and Knowledge Research Institute, Inc., 2131 Reflection Bay Drive, Arlington, Texas 76013, USA

Elisabeth H. Wiig

The service is nice and the time of processing the application is fast.

Department of Neurosurgery, Queen Elizabeth Hospital, Hong Kong

Long Ching

Your service is very good and fast reply, Also your service understand our situation and support us to publication our articles.

Palestine College of Nursing, Khan Younis, Gaza Strip, Palestine

Ayman M Abu Mustafa

“It was a delightful experience publishing my manuscript with the Clinical Journal of Obstetrics and Gynecology. They offered me lots of opportunities I never had from most publishing houses and their prompt services are greatly appreciated.”

Department of Agricultural Economics, Agribusiness and Extension, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

Akowuah Jones Asafo

View More

Related Journals

Help ?